



Drug Coverage Policy

Effective Date.....11/15/2025
Coverage Policy Number.....IP0102
Policy Title.....Sunosi

Wakefulness-Promoting Agents – Sunosi

- Sunosi® (solriamfetol tablets – Jazz)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

OVERVIEW

Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with **excessive daytime sleepiness** associated with the following conditions:¹

- **Narcolepsy.**
- **Obstructive sleep apnea (OSA).**

Limitations of Use: Sunosi is not indicated to treat the underlying airway obstruction in OSA.¹ The underlying airway obstruction should be treated (e.g., with continuous positive airway pressure [CPAP]) for at least 1 month prior to initiating Sunosi for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with Sunosi.

Sunosi is a Schedule IV controlled substance.¹

Armodafinil and modafinil are wakefulness-promoting agents with actions similar to sympathomimetic agents (e.g., amphetamine and methylphenidate).^{2,3} They are indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, OSA, or shift work disorder. Armodafinil and modafinil are Schedule IV controlled substances. Wakix® (pitolisant tablets), an antagonist/inverse agonist of the histamine-3 receptor, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for the treatment of excessive daytime sleepiness in pediatric patients ≥ 6 years of age with narcolepsy.¹³ Wakix is the only wakefulness-promoting agent that is not a controlled substance. Stimulant medications (e.g., amphetamine, methamphetamine, dextroamphetamine, and methylphenidate) are used off-label for the treatment of daytime sleepiness due to narcolepsy and OSA and are mentioned in guidelines.⁴⁻⁷

Two specialized tests, which can be performed in a sleep disorders clinic, are required to establish a diagnosis of narcolepsy.⁸ Polysomnogram (PSG) is an overnight recording of brain and muscle activity, breathing, and eye movements. The multiple sleep latency test assesses daytime sleepiness by measuring how quickly a person falls asleep and whether they enter rapid eye movement (REM) sleep. On the day after PSG, the patient is asked to take five short naps separated by 2 hours over the course of a day. If an individual falls asleep in < 8 minutes on average over the five naps, this indicates excessive daytime sleepiness. However, patients with narcolepsy also have an abnormally quick start to REM sleep. If REM sleep happens within 15 minutes at least two times out of the five naps and the sleep study the night before, this is likely an abnormality caused by narcolepsy.

Guidelines

Narcolepsy and Cataplexy

The American Academy of Sleep Medicine (AASM) practice parameters for the treatment of central disorders of hypersomnolence were updated in 2021.^{4,5}

- Modafinil, Wakix (pitolisant tablet), Xyrem® (sodium oxybate oral solution), and Sunosi are recommended as effective treatments for daytime sleepiness due to narcolepsy and reducing disease severity in adults (Strong Recommendation for each).
- Wakix and Xyrem have also demonstrated efficacy for the treatment of cataplexy in patients with narcolepsy (Strong Recommendation for each).
- Xyrem and armodafinil have Conditional Recommendations for the treatment of narcolepsy, showing efficacy for daytime sleepiness due to narcolepsy and reducing disease severity.
- Dextroamphetamine has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy for excessive daytime sleepiness and cataplexy.
- Methylphenidate has a Conditional Recommendation for the treatment of narcolepsy, showing efficacy in reducing disease severity.
- There was insufficient and inconclusive evidence to make recommendations for l-carnitine, scheduled naps, selegiline, triazolam, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs).
- Modafinil and Xyrem have Conditional Recommendations for the treatment of narcolepsy in pediatric patients.

- A Strong Recommendation should be followed by clinicians under most circumstances. A Conditional Recommendation requires that the clinician use clinical knowledge and experience and strongly consider the individual patient's values and preferences to determine the best course of action.

Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

- According to the AASM guideline on medical therapy for OSA (2006), CPAP is the most uniformly effective therapy, and, to date, this is the only intervention for OSA shown to have favorable impacts on both cardiovascular and neurobehavioral morbidities.^{6,7}
- Modafinil, in patients compliant with nasal CPAP, consistently improved subjective and objective sleepiness, quality of life, and vigilance compared with placebo.
- Sunosi is not addressed in these guidelines.
- According to the AASM guideline on treatment of adult obstructive sleep apnea (OSA) with positive airway pressure (PAP) [2019], PAP, compared with no therapy, is recommended to treat OSA in adults with excessive sleepiness (Strong Recommendation).
- PAP therapy is recommended to be initiated using either auto-titrating positive airway pressure (APAP) at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities (Strong Recommendation).
- Either CPAP or APAP is recommended for ongoing treatment of OSA in adults (Strong Recommendation).
- Use of CPAP or APAP over bilevel positive airway pressure (BPAP) is suggested in the routine treatment of OSA in adults (Conditional Recommendation).

Coverage Policy

POLICY STATEMENT

Prior Authorization is required for benefit coverage of Sunosi. This Prior Authorization Policy also contains a Step Therapy component. When clinically appropriate, the patient is directed to try one Step 1 Product (modafinil or armodafinil) prior to Sunosi (Step 2). All approvals are provided for the duration noted below.

Documentation: Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information.

Sunosi is considered medically necessary when ONE of the following is met:

FDA-Approved Indications

- 1. Excessive Daytime Sleepiness Associated with Narcolepsy.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, and E):
 - A)** Patient is ≥ 18 years of age; AND
 - B)** Patient has been evaluated using polysomnography and a multiple sleep latency test **[Documentation Required]**; AND
 - C)** Diagnosis of narcolepsy has been confirmed **[documentation required]**; AND
 - D)** The medication is prescribed by or in consultation with a sleep specialist physician or a neurologist; AND
 - E)** Patient has tried at least ONE of the following treatments: a central nervous system (CNS) stimulant, generic modafinil, or generic armodafinil **[Documentation Required]**.

Note: Examples of CNS stimulants include methylphenidate, dexamethylphenidate, and dextroamphetamine. An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.

- 2. Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea.** Approve for 1 year if the patient meets the following (A, B, and C):

A) Patient is ≥ 18 years of age; AND

B) Patient meets ONE of the following (i or ii):

i. Sunosi will be used in conjunction with positive airway pressure therapy; OR

ii. Patient is unable to initiate or tolerate positive airway pressure therapy

[Documentation Required]; AND

Note: Positive airway pressure can include continuous positive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), or bilevel positive airway pressure (BPAP).

C) Patient has tried generic modafinil or generic armodafinil **[Documentation Required]**.

Note: An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.

Conditions Not Covered

Sunosi for any other use is considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Concomitant Use of Sunosi with an Oxybate Product and/or Wakix (pitolisant tablets).** Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea.¹ Oxybate products include Xyrem (sodium oxybate oral solution), Lumryz (sodium oxybate extended-release oral suspension), and Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution).¹⁰⁻¹² These have the same active ingredient (oxybate, a central nervous system depressant) and have not been studied for use in combination or as alternating treatments. Wakix, an antagonist/inverse agonist of the histamine-3 receptor, is indicated for excessive daytime sleepiness and cataplexy in adults with narcolepsy.¹³ Currently, there are no published studies evaluating combination use of these medications.

References

1. Sunosi® tablets [prescribing information]. New York, NY: Axsome Therapeutics; June 2023.
2. Provigil® tablets [prescribing information]. Parsippany, NJ: Teva; December 2022.
3. Nuvigil® tablets [prescribing information]. Parsippany, NJ: Teva; December 2022.
4. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(9):1881-1893.
5. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med*. 2021;17(9):1895-1945.
6. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. *Sleep*. 2006;29(8):1031-1035.

7. Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2019;15(2):335-343.
8. National Institutes of Health. Narcolepsy. National Institute of Neurological Disorders and Stroke. Last reviewed on January 10, 2025. Available at: Narcolepsy | National Institute of Neurological Disorders and Stroke (nih.gov). Accessed on August 28, 2025.
9. Mayo Clinic. Obstructive sleep apnea. Available at: <https://www.mayoclinic.org/diseases-conditions/obstructive-sleep-apnea/symptoms-causes/syc-20352090?p=1>. Accessed on August 28, 2025.
10. Xyrem® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.
11. Lumryz™ extended-release oral suspension [prescribing information]. Chesterfield, MO: Avadel; October 2024.
12. Xywav® oral solution [prescribing information]. Palo Alto, CA: Jazz; April 2023.
13. Wakix® tablets [prescribing information]. Plymouth Meeting, PA: Harmony Biosciences; May 2025.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	Updated title from 'Solriamfetol' to 'Wakefulness-Promoting Agents – Sunosi' Excessive Daytime Sleepiness Associated with Narcolepsy. Updated 'Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy (Type 1 or 2)' TO 'Excessive Daytime Sleepiness Associated with Narcolepsy.' Added 'Diagnosis of narcolepsy has been confirmed, according to the prescriber' Removed 'Daily periods of irrepressible need to sleep or lapses into sleep during waking hours, occurring for at least three months' Updated 'Documentation of ONE of the following: (i) Diagnosis of narcolepsy type 1 and ONE of the following: (a) Mean Sleep Latency Test (MSLT) performed according to standard techniques, showing a mean sleep latency of less than or equal to 8 minutes <u>and</u> two or more sleep-onset rapid eye movement periods (SOREMPs) following a nocturnal polysomnogram (PSG) that rules out other causes of excessive daytime sleepiness, (b) A SOREMP (within 15 minutes of sleep onset) on a nocturnal PSG, (2) Diagnosis of narcolepsy type 2 and Mean Sleep Latency Test (MSLT) performed according to standard techniques, showing a mean sleep latency of less than or equal to 8 minutes <u>and</u> two or more sleep-onset rapid eye movement periods (SOREMPs) following a nocturnal polysomnogram (PSG) that rules out other causes of excessive daytime sleepiness. A SOREMP (within 15 minutes of sleep onset) on a nocturnal PSG may replace one of the SOREMPs on the MSLT' TO	10/15/2024

	'Patient has been evaluated using polysomnography and a multiple sleep latency test' Removed 'The hypersomnolence and/or MSLT findings are not better explained by other causes such as insufficient sleep, delayed sleep phase disorder, or the effect of medication or substances or their withdrawal' Updated 'Documentation of failure, contraindication, or intolerance to ONE of the following: (i) modafinil OR armodafinil, (ii) dextroamphetamine, dexmethylphenidate OR methylphenidate' TO 'Patient has tried generic modafinil or generic armodafinil. <u>Note</u>: An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.' Removed pulmonologist from 'Medication is prescribed by, or in consultation with' bullet Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea. Removed 'Daily periods of irrepressible need to sleep or lapses into sleep during waking hours, occurring for at least three months' Removed 'Documentation of diagnosis of Obstructive Sleep Apnea (OSA) is confirmed by sleep study' Removed 'The hypersomnolence and/or sleep study findings are not better explained by other causes such as insufficient sleep, delayed sleep phase disorder, or the effect of medication or substances or their withdrawal' Removed 'Sunosi will be used in combination with non-pharmacologic treatment for obstructive sleep apnea (OSA), unless contraindicated or intolerant' Updated 'Documentation of inadequate response to at least 1 month of non-pharmacologic treatment for OSA (for example, continuous positive airway pressure [CPAP])' TO 'Patient meets one of the following (i or ii): (i) Sunosi will be used in conjunction with continuous positive airway pressure (CPAP) therapy; OR (ii) Patient is unable to initiate or tolerate CPAP therapy' Updated 'Documentation of failure, contraindication, or intolerance to ONE of the following: (i) armodafinil, (ii) modafinil' TO 'Patient has tried generic modafinil or generic armodafinil. <u>Note</u>: An exception to this requirement is allowed if the patient has previously tried brand Provigil or brand Nuvigil.' Conditions Not Covered. Added 'Concomitant Use of Sunosi with an Oxybate Product and/or Wakix (pitolisant tablets).'	
Selected Revision	Excessive Daytime Sleepiness Associated with Narcolepsy.	11/01/2024

	The criteria were updated to include central nervous system (CNS) stimulants as an option for patients to have tried prior to approval of Sunosi. Now a patient needs to have tried a central nervous system (CNS) stimulant, generic modafinil, or generic armodafinil prior to approval of Sunosi. Previously, a patient had to have tried one of generic modafinil or generic armodafinil. Additionally, examples CNS stimulants were added to the Note.	
Selected Revision	Added "<u>Documentation</u>": Documentation is required where noted in the criteria. Documentation may include, but not limited to, chart notes, laboratory tests, claims records, and/or other information." Excessive Daytime Sleepiness Associated with Narcolepsy. Updated criteria from "Patient has been evaluated using polysomnography and a multiple sleep latency test" to "Documentation that the patient has been evaluated using polysomnography and a multiple sleep latency test." Updated criteria from "Diagnosis of narcolepsy has been confirmed, according to the prescriber" to "Documented diagnosis of narcolepsy has been confirmed." Updated criteria from "Patient has tried at least ONE of the following treatments: a central nervous system (CNS) stimulant, generic modafinil or generic armodafinil" to "Documentation that the patient has tried at least ONE of the following treatments: a central nervous system (CNS) stimulant, generic modafinil or generic armodafinil." Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea. Updated criteria from "Patient is unable to initiate or tolerate CPAP therapy" to "Documentation that the patient is unable to initiate or tolerate CPAP therapy." Updated criteria from "Patient has tried generic modafinil or generic armodafinil" to "Documentation that the patient has tried generic modafinil or generic armodafinil."	3/1/2025
Annual Revision	Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea. Requirement regarding use in conjunction with continuous positive airway pressure or patient is unable to initiate or tolerate continuous positive airway pressure was changed to use in conjunction with positive airway pressure or patient is unable to initiate or tolerate positive airway pressure with a Note that positive airway pressure can include continuous positive airway pressure (CPAP), auto-titrating positive airway pressure (APAP), or bilevel positive airway pressure (BPAP).	11/15/2025

	Updated documentation verbiage to “ [documentation required] .”	
--	--	--

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.